2-烯丙基-5-氯-1H-苯并咪唑 | 16405-85-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 中文名称: 2-烯丙基-5-氯-1H-苯并咪唑
• 英文名称: 2-Allyl-5-chloro-1H-benzoimidazole
• 英文别名: 2-Allyl-5-chloro-1H-benzo[d]imidazole；6-chloro-2-prop-2-enyl-1H-benzimidazole
• CAS: 16405-85-9
• 化学式: C₁₀H₉ClN₂
• 分子量: 192.648
• InChiKey: ZRCBMJMQRFPGQT-UHFFFAOYSA-N

物化性质

• 沸点：
  384.1±25.0 °C(Predicted)
• 密度：
  1.271±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  28.7
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Method for immunochemical measurement
  申请人：FUJI PHOTO FILM CO., LTD.

  公开号：EP0047470A1

  公开（公告）日：1982-03-17

  A method for immunochemical assay of an antigen or antibody by labelling the antigen or antibody with a specific cyanine or merocyanine dye containing a carboxy group followed by effecting an immune reaction and photochemical processing thereof is provided. The amount of the antigen or antibody is measured in term of optical density of developed silver halide which is brought into contact with either the antigen-antibody reaction product or the unreacted material. This immunochemial assay method gives high detection sensitivity in a simple operation manner.

  本发明提供了一种对抗原或抗体进行免疫化学检测的方法，即用含有羧基的特异性青色或梅洛青染料标记抗原或抗体，然后对其进行免疫反应和光化学处理。 抗原或抗体的量是通过与抗原-抗体反应产物或未反应物质接触的显影卤化银的光密度来测量的。 这种免疫化学检测方法操作简单，检测灵敏度高。
• Cyanine dyes for sensitizing silver halide emulsions to infrared radiation and photographic elements including them
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0088595A2

  公开（公告）日：1983-09-14

  Cyanine dyes including two nitrogen containing heterocyclic nuclei, linked to each other through a rigidized conjugated 7, 9 or 11 carbon atom methine chain to form an amidinium-ion resonance system, are very good for sensitizing silver halide emulsions for use in photographic elements to be exposed to infrared radiation if one of said heterocyclic nuclei is 5-methyl-6-methoxy-benzothiazole.

  如果所述杂环核之一是 5-甲基-6-甲氧基-苯并噻唑，那么包括两个含氮杂环核的氰基染料，通过刚性共轭的 7、9 或 11 个碳原子的甲基链相互连接，形成一个脒离子共振系统，非常适合于对卤化银乳剂进行感光，以用于暴露于红外辐射的摄影元件。
• COMBINATION THERAPY FOR TUMORAL DISEASE TREATMENT
  申请人：Ramot, at Tel Aviv University Ltd.

  公开号：EP2061464A2

  公开（公告）日：2009-05-27
• US5242790A
  申请人：——

  公开号：US5242790A

  公开（公告）日：1993-09-07
• [EN] COMBINATION THERAPY FOR TUMORAL DISEASE TREATMENT<br/>[FR] THÉRAPIE COMBINÉE POUR LE TRAITEMENT D'UNE MALADIE TUMORALE
  申请人：UNIV RAMOT

  公开号：WO2008032324A2

  公开（公告）日：2008-03-20

  [EN] The invention provides a method of treating cancer by administering to a subject in need thereof, the subject being treated with an anti-cancer antibody therapy, a therapeutically effective amount of a delocalized lipophilic cation (DLC) compound such as MKT-077 which is capable of binding mortalin as an adjuvant for the anti-cancer antibody therapy. Also provided are pharmaceutical compositions and article of manufacturer for treating cancer which comprise the DLC compound as an adjuvant for anti-cancer antibody therapy.
  [FR] L'invention porte sur un procédé qui permet de traiter le cancer en administrant à un sujet qui en a besoin, le sujet étant traité par une thérapie aux anticorps anticancéreux, une quantité thérapeutiquement efficace d'un composé à cations lipophiles délocalisés ("delocalized lipophilic cation" ou DLC) tel que le MKT-077, qui est capable de lier la mortaline, comme adjuvant dans la thérapie aux anticorps anticancéreux. L'invention concerne également des compositions pharmaceutiques et un article manufacturé permettant de traiter le cancer, qui comprennent le composé DLC comme adjuvant de la thérapie aux anticorps anticancéreux.